RCS - Angle PLC - Novel discoveries into the biology of cancer

AngleAnnouncement

10/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250610:nRSJ9965La&default-theme=true

RNS Number : 9965L  Angle PLC  10 June 2025

 For immediate release  10 June 2025

 

ANGLE plc ("the Company")

 

PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer

 

Academic and translational research is the driving force behind the pipeline
of next generation cancer therapeutics

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the publication of
three new peer-reviewed publications reporting first-in-class research into
the biology of cancer and potential therapeutic targets using the Company's
Parsortix system.

 

Tumour cell release during surgery for prostate cancer(1)

Professor Klaus Pantel and researchers from the University Medical Center
Hamburg-Eppendorf published an article in the Journal of Experimental &
Clinical Cancer Research, investigating tumour cell release into the local
tumour vein and peripheral veins during surgery in early-stage prostate cancer
patients. The study provides first evidence for substantial release of healthy
and cancerous cells into the blood during prostatectomy surgery. This research
opens a new avenue for the Parsortix system to study the important and
under-investigated biology of tumour cell release during surgery to understand
the risk they pose to patients, and for the development of strategies to
minimise the spread of cancer.

 

Tumour cell release during surgery for ovarian cancer(2)

Professor John O'Leary and researchers from Trinity College Dublin have
published similar findings in the European Journal of Surgical Oncology,
investigating CTC enrichment from the local tumour vein and peripheral veins
during surgery in rare epithelial ovarian carcinomas. They reported higher
yields of CTCs and CTC clusters in the local tumour vein when compared to
peripheral veins. The study also reported that CTCs were detected in
early-stage patients, highlighting the risk of early tumour cell dissemination
driving cancer progression even in the initial stages of disease. Overall, the
authors state that assessing tumour cell release during surgery is a novel
strategy to study the biology of this rare disease.

 

Mechanical conditioning & metastatic implications(3)

Professor Julie Lang and researchers from the Cleveland Clinic have published
an article in Cancers, investigating biomechanical adaptions of cells that are
associated with increased metastatic potential in breast cancer patients. They
studied the expression of 1004 genes via RNA-sequencing that reflect how
cancer cells respond to a stiff extracellular matrix described as a mechanical
conditioning score. The Parsortix system was utilised to enrich and harvest
CTCs from a metastatic cohort of breast cancer patients for analysis and
compared these to primary and metastatic tissue. The study analysed RNA from
CTCs rather than ctDNA to provide insight into gene expression. They state
that: 'When analyzing shed ctDNA, there is no insight into gene expression,
but rather only the presence of tumor-specific mutations, which is not
directly reflective of dynamic tumor gene expression. In fact, only a very
small percentage of DNA mutations are expressed, which is why circulating
tumor DNA and RNA from CTCs are not parallel assays'. The study reported that
the mechanical conditioning score increases progressively through the
metastatic cascade (from the primary tumour to CTCs to the metastatic site)
and is associated with increased metastatic potential. These are new insights
into the biology of metastatic progression and may guide treatment selection
with anti-fibrotic drugs.

 

Overall, these publications further underscore the role of the Parsortix
system in helping to advance our understanding of the biology of cancer which
will ultimately advance oncology drug discovery and development. Already
ANGLE's technology has enabled breakthrough research in a number of areas
including the metastatic potential of CTC clusters, new potential biomarkers
and a novel drug class. Academic and translational research discoveries made
possible by the Parsortix system, have the potential to feed the pipeline of
next generation personalised cancer diagnostics and therapeutics, as pharma
companies increasingly collaborate with academia(4).

 

 

ANGLE's Chief Scientific Officer, Karen Miller, commented:

"We are proud to see ANGLE's technology increasingly being exploited to make
novel discoveries into the biology of cancer, which may eventually result in
new treatment strategies. With advancing analytical capabilities beginning to
realise the vast potential of the circulating tumour cell for its wealth of
multiomic information, this contribution to the oncology pipeline will
continue to grow. We congratulate these key opinion leaders on their
outstanding work, and we look forward to more exciting discoveries in the
future."

 

1. Emurlai, G. et al. Comparative analysis of circulating tumor cells in
prostatic plexus and peripheral blood of patients undergoing prostatectomy. J.
Exp. Clin. Cancer Res. 44, 143 (2025).

 

2. Lewis, F. et al. A pilot study evaluating the feasibility of enriching and
detecting circulating tumour cells from peripheral and ovarian veins in rare
epithelial ovarian carcinomas. Eur. J. Surg. Oncol. 51, (2025).

 

3. Mouneimne, G. et al. Mechanical Conditioning (MeCo) Score Progressively
Increases Through the Metastatic Cascade in Breast Cancer via Circulating
Tumor Cells. Cancers 17, 1632 (2025).

 

4.
www.cen.acs.org/pharmaceuticals/drug-discovery/great-pharmaceutical-academic-merger/102/i31

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFIFETRFIAIIE